Black Bird Biotech, Inc.
BBBT · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.04 | -0.03 | 0.00 |
| FCF Yield | -416.28% | -22.82% | -10.79% | -0.51% |
| EV / EBITDA | -0.73 | -2.78 | -8.38 | -121.08 |
| Quality | ||||
| ROIC | -6,571.45% | -199.18% | -935.19% | 40.47% |
| Gross Margin | -67.71% | 18.75% | 50.97% | -0.17% |
| Cash Conversion Ratio | 0.62 | 0.55 | 0.90 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.75% | 80.47% | – | – |
| Free Cash Flow Growth | -3.45% | -61.13% | -617.60% | -13.44% |
| Safety | ||||
| Net Debt / EBITDA | -0.52 | 0.31 | 0.01 | -5.97 |
| Interest Coverage | -3.48 | -5.09 | -116.60 | -1.93 |
| Efficiency | ||||
| Inventory Turnover | 1.57 | 1.14 | 0.71 | 0.00 |
| Cash Conversion Cycle | -30.79 | 175.11 | -84.99 | -5,478.38 |